AU Patent

AU2022201921B2 — Crystalline forms of a LTA4H inhibitor

Assigned to Novartis AG · Expires 2023-08-03 · 3y expired

What this patent protects

CRYSTALLINE FORMS OF A LTA4H INHIBITOR. 5 ABSTRACT This application relates to various crystalline forms of (S)-3-amino-4-(5-(4-((5-chloro-3 fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid in its free form, as well as 0 compositions, method of making and method…

USPTO Abstract

CRYSTALLINE FORMS OF A LTA4H INHIBITOR. 5 ABSTRACT This application relates to various crystalline forms of (S)-3-amino-4-(5-(4-((5-chloro-3 fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid in its free form, as well as 0 compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ("hydrates"). These materials are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of LTA4H. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022201921B2
Jurisdiction
AU
Classification
—
Expires
2023-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.